Explore AstraZeneca's recent Form 6-K detailing CEO Pascal Soriot's transfer of 136,537 shares as a gift. Discover the implications for shareholder dynamics and regulatory compliance.
Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!
AstraZeneca's 6-K filing details the approval of new articles of association, enhancing capital access. Key voting results and future trading updates included.
Discover AstraZeneca's latest Form 6-K report on Euan Ashley's director appointment at DexCom. Key insights on governance and compliance included.
AstraZeneca's Koselugo gains European approval for adults with NF1, showing 20% efficacy in trials. This marks a significant step in addressing rare disease treatment needs.
Discover AstraZeneca's latest financial report detailing Saphnelo's positive CHMP review for SLE treatment, trial insights, and future growth potential in autoimmune diseases.
Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.
Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.
AstraZeneca PLC's August 2025 report corrects a TR-1 notification error. Shareholders should refer to the proper TR-1 from 21 August. Find details on their investor relations site.
Explore AstraZeneca's August 2025 Form 6-K detailing an insider share sale by CFO Aradhana Sarin. Key transaction insights and compliance with EU regulations included.
Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.